Study design
DISEASE
The clinical trial design comprised of two phases, 1A and 1B. In Phase 1A, the first 4 enrolled patients (3 patients with low-burden advanced disease and one with negative imaging and elevated Ct) were administered with the low mass amount of 10 μg [GRAN-T-MTC Trial design.Detailed physical examinations with vital sign assessment, 12-lead ECG, and laboratory testing were performed to investigate the safety of intravenous administration of [